PMCB Long Put Strategy

PMCB (PharmaCyte Biotech, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

PMCB (PharmaCyte Biotech, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.5M, a beta of 0.46 versus the broader market, a 52-week range of 0.63-1.51, average daily share volume of 142K, a public-listing history dating back to 2013, approximately 2 full-time employees. These structural characteristics shape how PMCB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.46 indicates PMCB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long put on PMCB?

A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.

Current PMCB snapshot

As of May 15, 2026, spot at $0.82, ATM IV 20.60%, IV rank 0.64%, expected move 5.91%. The long put on PMCB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long put structure on PMCB specifically: PMCB IV at 20.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a PMCB long put, with a market-implied 1-standard-deviation move of approximately 5.91% (roughly $0.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PMCB expiries trade a higher absolute premium for lower per-day decay. Position sizing on PMCB should anchor to the underlying notional of $0.82 per share and to the trader's directional view on PMCB stock.

PMCB long put setup

The PMCB long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PMCB near $0.82, the first option leg uses a $0.82 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PMCB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PMCB shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Put$0.82N/A

PMCB long put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.

PMCB long put payoff curve

Modeled P&L at expiration across a range of underlying prices for the long put on PMCB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long put on PMCB

Long puts on PMCB hedge an existing long PMCB stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying PMCB exposure being hedged.

PMCB thesis for this long put

The market-implied 1-standard-deviation range for PMCB extends from approximately $0.77 on the downside to $0.87 on the upside. A PMCB long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long PMCB position with one put per 100 shares held. Current PMCB IV rank near 0.64% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PMCB at 20.60%. As a Healthcare name, PMCB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PMCB-specific events.

PMCB long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PMCB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PMCB alongside the broader basket even when PMCB-specific fundamentals are unchanged. Long-premium structures like a long put on PMCB are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PMCB chain quotes before placing a trade.

Frequently asked questions

What is a long put on PMCB?
A long put on PMCB is the long put strategy applied to PMCB (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With PMCB stock trading near $0.82, the strikes shown on this page are snapped to the nearest listed PMCB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are PMCB long put max profit and max loss calculated?
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the PMCB long put priced from the end-of-day chain at a 30-day expiry (ATM IV 20.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PMCB long put?
The breakeven for the PMCB long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PMCB market-implied 1-standard-deviation expected move is approximately 5.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long put on PMCB?
Long puts on PMCB hedge an existing long PMCB stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying PMCB exposure being hedged.
How does current PMCB implied volatility affect this long put?
PMCB ATM IV is at 20.60% with IV rank near 0.64%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related PMCB analysis